|Bid||0.00 x 5000|
|Ask||0.00 x 28500|
|Day's Range||81.50 - 82.00|
|52 Week Range||56.51 - 90.24|
|PE Ratio (TTM)||59.85|
|Forward Dividend & Yield||0.72 (0.86%)|
|1y Target Est||N/A|
In December 2017, STADA Arzneimittel Aktiengesellschaft (DB:SAZ) released its most recent earnings update. Generally, analysts seem highly optimistic, with earnings expected to more than double in the upcoming year, relativeRead More...
Today I will be providing a simple run-through of the discounted cash flows (DCF) method to estimate the attractiveness of STADA Arzneimittel Aktiengesellschaft (DB:SAZ) as an investment opportunity. If youRead More...
Stada Arzneimittel AG will shop around for niche drug producers in central and eastern Europe to fuel expansion plans and boost regional sales growth as it cuts costs and shifts some production to its ...
Moody's Investors Service, ("Moody's") has today assigned a definitive B2 CFR and a new B2-PD Probability of default rating to Nidda BondCo GmbH (Nidda BondCo). The provisional ratings were assigned ...
Stada Arzneimittel AG will get its fifth chief executive officer in a little over two years as the German maker of copycat pills taps a Novartis AG manager to take over from Claudio Albrecht, who was brought ...
LONDON/FRANKFURT, Nov 30 (Reuters) - Swiss food giant Nestle and the private equity owners of German drug firm Stada are both preparing tentative bids for Merck KgaA's consumer health unit, several sources told Reuters. Merck's financial adviser JPMorgan has invited bids for the business, which is valued at about 4 billion euros ($4.8 billion), ahead of a Dec. 15 deadline, the sources said. Nestle is widely seen as a natural buyer for the maker of Seven Seas vitamins and Bion nutritional supplements, after previous talks to set up a consumer joint venture with Merck fell through over the summer.
Categories: Europe Stock Alerts Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for STADA Arzneimittel AG. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)
Leveraged loan issuance in Europe this year has surpassed the whole of 2016, after a series of major mergers and acquisitions added fuel to the booming market.
CVC Capital Partners and other private equity owners are exploring options for generic drugmaker Alvogen, including a sale, which could be valued at about $4 billion, Bloomberg reported on Tuesday. Alvogen's controlling shareholders have held talks with Shanghai Pharmaceuticals Holding Co for the sale of Alvogen's U.S. business, Bloomberg said, citing people familiar with the matter. The drugmaker will keeps its Asian and central European operations, Bloomberg reported.
Rating Action: Moody's assigns B2 CFR to Nidda BondCo GmbH, outlook stable. Global Credit Research- 07 Sep 2017. Frankfurt am Main, September 07, 2017-- Moody's Investors Service, has today assigned a ...
Buyout groups Bain Capital and Cinven said they would propose to Stada's management to offer minority shareholders cash compensation of 74.40 euros per share, giving in to pressure from activist investor Elliott. Bain and Cinven last month won control of German generic drug maker Stada with a sweetened 5.3 billion-euro ($6.3 billion) bid, in the largest private-equity funded takeover of a German listed company, offering 66.25 euros per share. Elliott Management had said on Thursday, however, that it wanted at least 74.40 euros per share for its stake, which most recently stood at 13.3 percent, or 15.2 percent when taking stock options into account.
Activist investor Elliott Management said on Thursday it wanted at least 74.40 euros per share for its stake in Stada as private equity firms Bain Capital and Cinven seek to tighten their grip on the German generic drugmaker. Bain and Cinven this month won control of Stada with a sweetened 5.3 billion-euro ($6.3 billion) bid, in the largest private-equity funded takeover of a German listed company, offering 66.25 euros per share.
Activist investors Elliott said it would not support a domination agreement between Stada and its buyers if compensation for minority shareholders was not at least 74.40 euros per share. Bain Capital and ...
Oct.06 -- Claudio Albrecht, CEO at Stada Arzneimittel, discusses plans to take the company into new territory to build top line growth. He speaks on "Bloomberg Markets: European Open.."